Payment overview · 2025
General Payments
$2,019.80
81 reported records · 24 companies
Healthcare provider profile · identity verified
Daksha C Vyas, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology with Special Qualifications in Child Neurology · MERRILLVILLE, IN · NPI 1922190859
Verified facts
What the public records show
CMS Open Payments records show Daksha C Vyas, M.D. received $2,019.80 in general payments during 2025 across 81 reported records.
Takeda Pharmaceuticals U.S.A., Inc. accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ubrelvy, Valtoco.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ubrelvy by this doctor in 2024.
Neurelis, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VALTOCO as an associated drug or biological on 16082 records involving 5567 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Valtoco by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $412.70 | 20.4% | 15 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $305.78 | 15.1% | 16 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $154.88 | 7.7% | 7 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$143.79 | 7.1% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $129.76 | 6.4% | 5 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $123.90 | 6.1% | 6 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $88.15 | 4.4% | 3 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $65.24 | 3.2% | 3 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $58.52 | 2.9% | 2 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $57.53 | 2.9% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $55.96 | 2.8% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $52.25 | 2.6% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $51.20 | 2.5% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $51.03 | 2.5% | 2 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$42.79 | 2.1% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $38.60 | 1.9% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $37.15 | 1.8% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.60 | 1.4% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $23.54 | 1.2% | 1 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $22.25 | 1.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.05 | 1.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.74 | 1.0% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $18.49 | 0.9% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $17.90 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,001.90 | 80 |
| Education | $17.90 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $412.70 | 15 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $169.81 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $159.04 | 9 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $135.97 | 8 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $135.44 | 6 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $135.44 | 6 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $129.76 | 5 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $99.26 | 5 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $88.15 | 3 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $88.15 | 3 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $65.24 | 3 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $57.53 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $55.96 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $51.20 | 1 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $51.03 | 2 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $42.79 | 1 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $38.60 | 1 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $34.37 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $28.60 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $24.64 | 1 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $23.54 | 1 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $22.25 | 1 | 2025 |
Source payment records
|
|||||
| KENGREAL Normalized: kengreal |
Drug | Chiesi USA, Inc. | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.05 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| CLEVIPREX Normalized: cleviprex |
Drug | Chiesi USA, Inc. | $17.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 45 | exact normalized | Medicare Part D |
| VALTOCO valtoco |
2025 | Valtoco | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
| Neurelis, Inc. Exact reporting entity; no affiliate inference |
2025 | VALTOCO open payments reported associated product |
CMS Open Payments — General Payments 16082 supporting records · 5567 recipient NPIs · example record 1219183925 |
Valtoco · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 410 | 99 |
| Levetiracetam | Levetiracetam | 207 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 203 | 55 |
| Donepezil Hcl | Donepezil Hcl | 182 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 120 | 43 |
| Lacosamide | Lacosamide | 119 | 23 |
| Pregabalin | Pregabalin | 105 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 101 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 85 | 22 |
| Naproxen | Naproxen | 79 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 76 | 15 |
| Atorvastatin Calcium | Atorvastatin Calcium | 66 | 21 |
| Alprazolam | Alprazolam | 64 | 22 |
| Rizatriptan | Rizatriptan Benzoate | 58 | 20 |
| Memantine Hcl Er | Memantine Hcl | 56 | suppressed |
| Lamotrigine | Lamotrigine | 55 | 12 |
| Baclofen | Baclofen | 54 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 18 |
| Trazodone Hcl | Trazodone Hcl | 51 | 14 |
| Oxcarbazepine | Oxcarbazepine | 50 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 48 | 13 |
| Topiramate | Topiramate | 47 | 16 |
| Clonazepam | Clonazepam | 45 | suppressed |
| Ubrelvy | Ubrogepant | 45 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | 11 |
| Meclizine Hcl | Meclizine Hcl | 40 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 38 | suppressed |
| Primidone | Primidone | 38 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 35 | 12 |
| Phenobarbital | Phenobarbital | 35 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 35 | suppressed |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 31 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | 17 |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 26 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | 12 |
| Risperidone | Risperidone | 22 | suppressed |
| Prednisone | Prednisone | 21 | suppressed |
| Modafinil | Modafinil | 20 | suppressed |
| Dalfampridine Er | Dalfampridine | 19 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | suppressed |
| Levetiracetam Er | Levetiracetam | 19 | suppressed |
| Teriflunomide | Teriflunomide | 19 | suppressed |
| Carbamazepine Er | Carbamazepine | 18 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Omeprazole | Omeprazole | 17 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 16 | suppressed |
| Amantadine | Amantadine Hcl | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Clobazam | Clobazam | 14 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 14 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Valtoco | Diazepam | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 11 | suppressed |
| Glatopa | Glatiramer Acetate | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,019.80 · 81 records | Takeda Pharmaceuticals U.S.A., Inc. | AMYVID, AUSTEDO XR, BOTOX, CLEVIPREX, EPIDIOLEX, HYQVIA, KENGREAL, KESIMPTA, KISUNLA, LEQVIO, Leqembi, Motpoly XR, Ocrevus Zunovo, PURIFIED CORTROPHIN GEL, QULIPTA, Symbravo, TRELEGY ELLIPTA, TRUDHESA, TYSABRI, Tascenso ODT, UBRELVY, ULTOMIRIS, VALTOCO, VUMERITY, VYVGART, VYVGART HYTRULO, ZEPOSIA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ubrelvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error